Form 4: UTHR Director Exercises Options, Sells Shares

United Therapeutics Director Tommy G Thompson exercised stock options and subsequently sold a portion of his common stock holdings on March 26, 2026.

Summary

• Tommy G Thompson, a Director of United Therapeutics Corp, reported transactions on March 26, 2026.
• Exercised stock options to acquire 2,000 shares of common stock at an exercise price of $101.8 per share.
• Sold a total of 2,000 shares of common stock in multiple transactions at weighted average prices ranging from $537.6192 to $540.175 per share.
• The transactions were made pursuant to a Rule 10b5-1 plan.
• Following these transactions, Mr. Thompson directly beneficially owns 8,480 shares of common stock.
• Additionally, 8,200 shares are indirectly owned by a Trust and 5,800 shares by a Family LLC.
• Includes 880 shares of common stock to be issued around July 8, 2026, resulting from the July 7, 2023, vesting of RSUs for which receipt was deferred.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be perceived negatively, the transaction involved an option exercise and was conducted under a Rule 10b5-1 plan, suggesting a pre-planned liquidity event rather than a reaction to new company-specific information.

Positives

• Exercise of stock options at a significantly lower price ($101.8) compared to the sale price (over $537) indicates a substantial gain for the insider.
• The transactions were conducted under a Rule 10b5-1 plan, suggesting pre-planned sales and not necessarily a reaction to new, undisclosed negative information.

Negatives

• The net effect of the reported transactions is a decrease in direct beneficial ownership of common stock by 2,000 shares (2,000 acquired, 2,000 sold).

Future Outlook

880 shares of common stock are expected to be issued on or about July 8, 2026, as a result of the July 7, 2023, vesting of RSUs for which the reporting person elected to defer receipt.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving option exercises and subsequent sales, are common events for executives and directors. These often reflect personal financial planning, diversification, or tax management rather than a direct signal about the company's immediate operational performance or future prospects. The use of a Rule 10b5-1 plan further supports this interpretation, indicating a pre-scheduled transaction.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of exercising stock options and selling shares for liquidity or diversification is standard across industries for executives and directors. For example, similar transactions are routinely reported by insiders at large pharmaceutical companies like Pfizer or biotech firms such as Amgen, where long-term equity compensation is a significant part of executive pay.
• The prices involved reflect the market value of UTHR shares at the time of the transaction, which would be compared to peer valuations in a broader market analysis, but this Form 4 itself does not provide such comparative data.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 8,200 shares by a Trust and 5,800 shares by a Family LLC, indicating holdings through related entities.

Stakeholder Impact

• Shareholders may note the director's sale of shares, which could be interpreted in various ways, though the Rule 10b5-1 plan mitigates concerns about opportunistic selling.

Next Steps

• Issuance of 880 deferred RSU shares on or about July 8, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, insider trading, stock options, common stock, director, Tommy G Thompson, Rule 10b5-1, share sale, equity